Use of an Online Community to Develop Patient-Reported Outcome Instruments: The Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)

Background Patients with multiple sclerosis (MS) may face barriers, such as treatment fatigue, memory problems, or side effects, that may influence their adherence to medication. Objective The objective of our study was to use an online community to develop a self-report questionnaire to quantify adherence and barriers to achieving adherence, that is specific to MS disease-modifying treatments (DMTs) and predictive of missed doses. Methods A review of the scientific literature and analysis of discussions between MS patients on PatientsLikeMe.com were used to generate survey items salient to patients. Cognitive debriefing was used to refine the items. The Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ) contains 30 questions in three subscales: Barriers, Side Effects, and Coping Strategies. Results MS patients completed an online survey (response rate: 431 of 1209 invited, 35.7%). Between 16% (14/86) and 51% (51/100) of MS patients missed at least 1 dose of their DMT in the previous 28 days, with significant between-treatment differences. The MS-TAQ Barriers scale was positively correlated with the proportion of doses missed (r = .5), demonstrating a stronger relationship between adherence and perceived barriers than was found with clinical or demographic variables (r ≈ .3). The Coping Strategies subscale was negatively correlated with missed doses (r = -.3), suggesting that use of more coping strategies is associated with higher adherence. Conclusions Online communities can provide domains of interest and psychometric data to more rapidly develop and prototype patient-reported outcome instruments. The MS-TAQ offers patients and clinicians a simple method for identifying barriers to adherence, which may then be targeted through interventions.

[1]  D. Cox,et al.  A Prospective Baseline Versus On‐Treatment Study Assessing Patient Perceptions of Using a Smaller Needle When Injecting Intramuscular Interferon Beta‐1a (Avonex) , 2008, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[2]  Gunther Eysenbach,et al.  Improving the Quality of Web Surveys: The Checklist for Reporting Results of Internet E-Surveys (CHERRIES) , 2004, Journal of medical Internet research.

[3]  James R. Miller The importance of early diagnosis of multiple sclerosis. , 2004, Journal of managed care pharmacy : JMCP.

[4]  D. Mohr,et al.  Teaching patients to self-inject: pilot study of a treatment for injection anxiety and phobia in multiple sclerosis patients prescribed injectable medications. , 2002, Journal of behavior therapy and experimental psychiatry.

[5]  Jared M. Bruce,et al.  Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report , 2010, Multiple sclerosis.

[6]  A. al‐Sabbagh,et al.  Patient satisfaction with an injection device for multiple sclerosis treatment , 2006, Acta neurologica Scandinavica.

[7]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[8]  G. Willis,et al.  Cognitive Interviewing: A Tool for Improving Questionnaire Design , 2004 .

[9]  S. De Geest,et al.  Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[10]  P. Fontoura,et al.  The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis , 2011, European journal of neurology.

[11]  J. Frost,et al.  Sharing Health Data for Better Outcomes on PatientsLikeMe , 2010, Journal of medical Internet research.

[12]  D. Hoaglin,et al.  The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics , 2006, Multiple sclerosis.

[13]  D. Cox,et al.  Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. , 2006, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[14]  D. Wingerchuk,et al.  Current Evidence and Therapeutic Strategies for Multiple Sclerosis , 2008, Seminars in neurology.

[15]  X. Montalban,et al.  Interferon beta in secondary progressive multiple sclerosis , 2007, Journal of Neurology.

[16]  Yelena Rozenfeld,et al.  Oral antidiabetic medication adherence and glycemic control in managed care. , 2008, The American journal of managed care.

[17]  P. Laurent,et al.  A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis , 2008, BMC neurology.

[18]  R. Marrie,et al.  Validation of the NARCOMS registry: diagnosis , 2007, Multiple sclerosis.

[19]  J. Haselkorn,et al.  Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model , 2007, Multiple sclerosis.

[20]  P. Vermersch,et al.  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[21]  Arthur L. Allen,et al.  Factors that influence adherence with disease-modifying therapy in MS , 2009, Journal of Neurology.

[22]  Kathleen Costello,et al.  Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. , 2008, Medscape journal of medicine.

[23]  X. Montalban,et al.  Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis , 2005, Multiple sclerosis.

[24]  C. McHorney,et al.  Frequency of and reasons for medication non‐fulfillment and non‐persistence among American adults with chronic disease in 2008 , 2011, Health expectations : an international journal of public participation in health care and health policy.

[25]  Paul Wicks,et al.  The power of social networking in medicine , 2009, Nature Biotechnology.

[26]  D. Goodkin,et al.  Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and infection anxiety on adherence and ability to self-inject , 2001, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[27]  M. Dimatteo Variations in Patients’ Adherence to Medical Recommendations: A Quantitative Review of 50 Years of Research , 2004, Medical care.

[28]  Ludwig Kappos,et al.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[29]  F. Reed Johnson,et al.  Multiple sclerosis patients—benefit-risk preferences: Serious adverse event risks versus treatment efficacy , 2009, Journal of Neurology.

[30]  R. Marrie,et al.  Validation of the NARCOMS Registry: fatigue assessment , 2005, Multiple sclerosis.

[31]  H. Tremlett,et al.  Interrupted therapy , 2003, Neurology.

[32]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[33]  M Hutchinson,et al.  Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns , 2005, Multiple sclerosis.

[34]  T. Berger ‘Let’s stick together’
Adherence to disease‐modifying therapies in multiple sclerosis , 2011, European journal of neurology.

[35]  D. Mohr,et al.  Self-Injection Anxiety Training: a treatment for patients unable to self-inject injectable medications , 2005, Multiple sclerosis.

[36]  T. Dwyer,et al.  Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses , 2008, Pharmacoepidemiology and drug safety.

[37]  Jeffrey A Cohen,et al.  Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease. , 2006, Cleveland Clinic journal of medicine.

[38]  Sally Okun,et al.  Patient-reported Outcomes as a Source of Evidence in Off-Label Prescribing: Analysis of Data From PatientsLikeMe , 2011, Journal of medical Internet research.

[39]  Jared M. Bruce,et al.  Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition , 2010, Journal of Behavioral Medicine.